IntroductionUnmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as ...
Plimsoll Publishing Ltd | 150 pages | February 2008 | English
The Plimsoll Portfolio Analysis - Alternative Medicines & Therapies is a comprehensive evaluation of the UK market. The revised and updated 2008 edition analyses the financial performance of the co ...
Koncept Analytics | 35 pages | June 2008 | English
This Competitive Intelligence Report helps you to know more about your company, your industry, and your competitors. It makes you better informed about important issues like launching a new product ...
A Partneringdesk Deals Briefing provides an in-depth view of all the deals made by the company and its subsidiaries between 2001 and 2006, in a clear and accessible PDF format.Chapter 1: Company profi ...
Datamonitor's Eli Lilly and Company Company Profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, hist ...
IntroductionFollowing the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to ...
IntroductionDatamonitor's PharmaVitae Japanese Comparator Tool builds from the PharmaVitae profiles included in the report 'Japanese Pharma to 2010'. This new tool allows you to compare the 15 lead ...
Functional foods i.e. those that claim to have other health benefits in addition to their nutritional value tend to be promoted mainly as being able to help prevent heart disease, digestive pro ...
China's demand for vitamins and supplements has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's ...
A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been ...
